menu
    • menu
    [{"orgOrder":0,"company":"Nasus Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"ISRAEL","productType":"Hormone","year":"2021","type":"Inapplicable","leadProduct":"Epinephrine","moa":"Adrenergic receptor","graph1":"Immunology","graph2":"Phase II\/ Phase III","graph3":"Nasus Pharma","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Nasus Pharma \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Nasus Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Nasus Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"ISRAEL","productType":"Hormone","year":"2023","type":"Inapplicable","leadProduct":"Epinephrine","moa":"Adrenergic receptor","graph1":"Immunology","graph2":"Phase II\/ Phase III","graph3":"Nasus Pharma","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Spray","sponsorNew":"Nasus Pharma \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Nasus Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Nasus Pharma","sponsor":"Hadassah Medical Organization | Medis | Pharma Medica Research","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"ISRAEL","productType":"Hormone","year":"2024","type":"Inapplicable","leadProduct":"Epinephrine","moa":"Adrenergic receptor","graph1":"Immunology","graph2":"Phase II\/ Phase III","graph3":"Nasus Pharma","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Nasus Pharma \/ Hadassah Medical Organization | Medis | Pharma Medica Research","highestDevelopmentStatusID":"9","companyTruncated":"Nasus Pharma \/ Hadassah Medical Organization | Medis | Pharma Medica Research"},{"orgOrder":0,"company":"Nasus Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"ISRAEL","productType":"Hormone","year":"2025","type":"Inapplicable","leadProduct":"Epinephrine","moa":"Adrenergic receptor","graph1":"Immunology","graph2":"Phase II\/ Phase III","graph3":"Nasus Pharma","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Powder","sponsorNew":"Nasus Pharma \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Nasus Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Nasus Pharma","sponsor":"Laidlaw & Company","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"ISRAEL","productType":"Hormone","year":"2025","type":"Public Offering","leadProduct":"Epinephrine","moa":"Adrenergic receptor","graph1":"Immunology","graph2":"Phase II\/ Phase III","graph3":"Nasus Pharma","amount2":0.01,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Immunology","amount2New":0.01,"dosageForm":"Injection","sponsorNew":"Nasus Pharma \/ Laidlaw & Company","highestDevelopmentStatusID":"9","companyTruncated":"Nasus Pharma \/ Laidlaw & Company"},{"orgOrder":0,"company":"Nasus Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"ISRAEL","productType":"Carbohydrate","year":"2020","type":"Inapplicable","leadProduct":"Hydroxypropyl Methyl Cellulose","moa":"Epithelial cell","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Nasus Pharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Spray","sponsorNew":"Nasus Pharma \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Nasus Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Nasus Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"ISRAEL","productType":"Carbohydrate","year":"2020","type":"Inapplicable","leadProduct":"Hydroxypropyl Methyl Cellulose","moa":"Epithelial cell","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Nasus Pharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Spray","sponsorNew":"Nasus Pharma \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Nasus Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Nasus Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"ISRAEL","productType":"Carbohydrate","year":"2021","type":"Inapplicable","leadProduct":"Hydroxypropyl Methyl Cellulose","moa":"Epithelial cell","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Nasus Pharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Spray","sponsorNew":"Nasus Pharma \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Nasus Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Nasus Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"ISRAEL","productType":"Carbohydrate","year":"2021","type":"Inapplicable","leadProduct":"Hydroxypropyl Methyl Cellulose","moa":"Epithelial cell","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Nasus Pharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Spray","sponsorNew":"Nasus Pharma \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Nasus Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Nasus Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"ISRAEL","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"FMXIN001","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"Nasus Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Spray","sponsorNew":"Nasus Pharma \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Nasus Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Nasus Pharma","sponsor":"Aptar","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"ISRAEL","productType":"Hormone","year":"2025","type":"Agreement","leadProduct":"Epinephrine","moa":"Adrenergic receptor","graph1":"Immunology","graph2":"Phase II\/ Phase III","graph3":"Nasus Pharma","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Powder","sponsorNew":"Nasus Pharma \/ Aptar","highestDevelopmentStatusID":"9","companyTruncated":"Nasus Pharma \/ Aptar"}]

    Find Clinical Drug Pipeline Developments & Deals by Nasus Pharma

    Menu

    Nasus Pharma

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Nasus Pharma

                            Israel arrow
                            Indonesia Pharmaceutical Expo
                            Not Confirmed

                            Nasus Pharma

                            Israel arrow
                            Indonesia Pharmaceutical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Epinephrine

                            Therapeutic Area : Immunology

                            Study Phase : Phase II

                            Sponsor : Aptar

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            Nasus Announces Expanded Agreement to Support Development and Commercialization of NS002

                            Details : As part of the agreement, Epinephrine, a hormone targeting adrenergic receptors, will focus on addressing anaphylaxis.

                            Product Name : NS002

                            Product Type : Hormone

                            Upfront Cash : Undisclosed

                            October 08, 2025

                            Lead Product(s) : Epinephrine

                            Therapeutic Area : Immunology

                            Highest Development Status : Phase II

                            Sponsor : Aptar

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Nasus Pharma

                            Israel arrow
                            Indonesia Pharmaceutical Expo
                            Not Confirmed

                            Nasus Pharma

                            Israel arrow
                            Indonesia Pharmaceutical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Epinephrine

                            Therapeutic Area : Immunology

                            Study Phase : Phase II

                            Sponsor : Laidlaw & Company

                            Deal Size : $10.0 million

                            Deal Type : Public Offering

                            DEALS_DEV arrow-down

                            Nasus Pharma Announces Closing of Initial Public Offering

                            Details : The Company intends to use the net proceeds to develop further its intranasal Epinephrine program, NS002, which is being developed for patients with anaphylaxis.

                            Product Name : NS002

                            Product Type : Hormone

                            Upfront Cash : Undisclosed

                            August 14, 2025

                            Lead Product(s) : Epinephrine

                            Therapeutic Area : Immunology

                            Highest Development Status : Phase II

                            Sponsor : Laidlaw & Company

                            Deal Size : $10.0 million

                            Deal Type : Public Offering

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Nasus Pharma

                            Israel arrow
                            Indonesia Pharmaceutical Expo
                            Not Confirmed

                            Nasus Pharma

                            Israel arrow
                            Indonesia Pharmaceutical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Epinephrine

                            Therapeutic Area : Immunology

                            Study Phase : Phase II/ Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            FMXIN002 in Patients at Risk of Anaphylaxis

                            Details : Epinephrine is a Hormone drug candidate, which is currently being evaluated in Phase II/ Phase III clinical studies for the treatment of Anaphylaxis.

                            Product Name : Undisclosed

                            Product Type : Hormone

                            Upfront Cash : Inapplicable

                            July 01, 2025

                            Lead Product(s) : Epinephrine

                            Therapeutic Area : Immunology

                            Highest Development Status : Phase II/ Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Nasus Pharma

                            Israel arrow
                            Indonesia Pharmaceutical Expo
                            Not Confirmed

                            Nasus Pharma

                            Israel arrow
                            Indonesia Pharmaceutical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Epinephrine

                            Therapeutic Area : Immunology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Hadassah Medical Organization | Medis | Pharma Medica Research

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Comparative Bioavailability of Intranasal Epinephrine

                            Details : Epinephrine is a Hormone drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of Anaphylaxis.

                            Product Name : Undisclosed

                            Product Type : Hormone

                            Upfront Cash : Inapplicable

                            January 12, 2024

                            Lead Product(s) : Epinephrine

                            Therapeutic Area : Immunology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Hadassah Medical Organization | Medis | Pharma Medica Research

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Nasus Pharma

                            Israel arrow
                            Indonesia Pharmaceutical Expo
                            Not Confirmed

                            Nasus Pharma

                            Israel arrow
                            Indonesia Pharmaceutical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Epinephrine

                            Therapeutic Area : Immunology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Nasus Pharma Announces Positive Clinical Results of Recent Phase 2 Study With FMXIN002 Intranasal Epinephrine

                            Details : FMXIN002 (epinephrine) is an adrenergic receptor agonist small molecule drug candidate, which is currently being evaluated for the treatment of anaphylaxis via intranasal spray.

                            Product Name : Undisclosed

                            Product Type : Hormone

                            Upfront Cash : Inapplicable

                            December 05, 2023

                            Lead Product(s) : Epinephrine

                            Therapeutic Area : Immunology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Nasus Pharma

                            Israel arrow
                            Indonesia Pharmaceutical Expo
                            Not Confirmed

                            Nasus Pharma

                            Israel arrow
                            Indonesia Pharmaceutical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Hydroxypropyl Methyl Cellulose

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Approved FDF

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Taffix® Regains Marketing Approval in Spain

                            Details : Taffix powder creates a unique thin acidified gel above the nasal mucosa that lasts 5 hours, significantly shielding the nasal cells from inhaled viruses through both mechanical and chemical protection.

                            Product Name : TaffiX

                            Product Type : Carbohydrate

                            Upfront Cash : Inapplicable

                            August 16, 2021

                            Lead Product(s) : Hydroxypropyl Methyl Cellulose

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Approved FDF

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Nasus Pharma

                            Israel arrow
                            Indonesia Pharmaceutical Expo
                            Not Confirmed

                            Nasus Pharma

                            Israel arrow
                            Indonesia Pharmaceutical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Hydroxypropyl Methyl Cellulose

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Approved FDF

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Taffix® Regains Marketing Approval in Spain

                            Details : Taffix® powder creates a unique thin acidified gel above the nasal mucosa that lasts 5 hours, significantly shielding the nasal cells from inhaled viruses through both mechanical and chemical protection.

                            Product Name : Taffix

                            Product Type : Carbohydrate

                            Upfront Cash : Inapplicable

                            August 16, 2021

                            Lead Product(s) : Hydroxypropyl Methyl Cellulose

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Approved FDF

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Nasus Pharma

                            Israel arrow
                            Indonesia Pharmaceutical Expo
                            Not Confirmed

                            Nasus Pharma

                            Israel arrow
                            Indonesia Pharmaceutical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : FMXIN001

                            Therapeutic Area : Psychiatry/Psychology

                            Study Phase : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Single-Dose, Bioequivalence Study of FMXIN001 4 mg Microspheres Powder

                            Details : FMXIN001 is a drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Opiate Overdose.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            January 19, 2021

                            Lead Product(s) : FMXIN001

                            Therapeutic Area : Psychiatry/Psychology

                            Highest Development Status : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Nasus Pharma

                            Israel arrow
                            Indonesia Pharmaceutical Expo
                            Not Confirmed

                            Nasus Pharma

                            Israel arrow
                            Indonesia Pharmaceutical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Epinephrine

                            Therapeutic Area : Immunology

                            Study Phase : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Bioavailability of Nasal Epinephrine

                            Details : Epinephrine is a Hormone drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Anaphylaxis.

                            Product Name : Undisclosed

                            Product Type : Hormone

                            Upfront Cash : Inapplicable

                            January 06, 2021

                            Lead Product(s) : Epinephrine

                            Therapeutic Area : Immunology

                            Highest Development Status : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            Nasus Pharma

                            Israel arrow
                            Indonesia Pharmaceutical Expo
                            Not Confirmed

                            Nasus Pharma

                            Israel arrow
                            Indonesia Pharmaceutical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Hydroxypropyl Methyl Cellulose

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Approved FDF

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Nasus Pharma Announces First Clinical Data Demonstrating Efficacy of Taffix™ Intranasal Antiviral Protection...

                            Details : Data from a prospective clinical post marketing users survey shows that TaffixTM effectively blocks viruses from reaching nasal mucosa and was able to reduce infection rate of SARS-CoV-2 virus after super spread event by at least 4 fold.

                            Product Name : TaffiX

                            Product Type : Carbohydrate

                            Upfront Cash : Inapplicable

                            October 13, 2020

                            Lead Product(s) : Hydroxypropyl Methyl Cellulose

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Approved FDF

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth